青岛海泰新光科技股份有限公司 章 程 2025 年 8 月 中国·青岛 | | | 青岛海泰新光科技股份有限公司 章 程 第一章 总 则 第一条 为维护青岛海泰新光科技股份有限公司、股东、职工和债权人的合法 权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和 国外商投资法》、《外商投资企业设立及变更备案管理暂行办法》、《上海证券交易 所科创板股票上市规则》、《上市公司章程指引》和其他有关规定，制定本章程。 第二条 青岛海泰新光科技股份有限公司（以下简称"公司"或"上市公司"）系依 照《公司法》和其他有关规定成立的股份有限公司。公司系由青岛海泰新光科技有限 公司依法整体变更设立的股份公司；公司在青岛市工商管理局注册登记，取得营业执 照，统一社会信用代码为：91370200747243684J。 第三条 公司于 2021 年 1 月 12 日经中国证监会同意注册，首次向社会公众发 行人民币普通股 21,780,000 股，于 2021 年 2 月 26 日在上海证券交易所科创板上市。 第四条 公司注册中文名称：青岛 ...

青岛海泰新光科技股份有限公司董事和高级管理人员薪酬管理制度 第四条 本制度适用的对象包括： （一）公司董事长、董事（独立董事除外）； 青岛海泰新光科技股份有限公司 董事和高级管理人员薪酬管理制度 青岛海泰新光科技股份有限公司（以下简称"公司"）为激励董事、高级 管理人员诚信、勤勉地履行岗位职责，完善公司治理结构和激励约束机制，提 高公司的经营管理水平，有效调动公司董事、高级管理人员的工作积极性，保 障公司持续、稳定、健康的发展，结合公司实际，制定本制度。 第一章 薪酬制定原则 第一条 体现个人薪酬水平与公司业绩和工作目标、责任大小相结合的原 则，强化员工的目标责任意识，促进公司和部门的整体绩效提高。 第二条 体现按劳分配原则，促进持续不断的创新，保证薪酬与价值创造 和 贡献大小相符。 第三条 体现个人薪酬与公司长远利益相结合的原则，提高公司品牌形象， 保证薪酬与公司持续健康发展的目标相符。 第二章 本制度适用的对象 （二）公司总经理、副总经理、财务总监、董事会秘书以及公司章程认定 的其他高级管理人员。 第三章 薪酬管理机构 第五条 公司董事会薪酬与考核委员会是对董事、高级管理人员进行薪酬 和考核管理的机构。薪 ...

青岛海泰新光科技股份有限公司董事会议事规则 青岛海泰新光科技股份有限公司 董事会议事规则 第一章 总 则 第一条 为规范青岛海泰新光科技股份有限公司（以下简称"公司"）董事 会的议事程序，保证董事会落实股东会决议，提高董事会的工作效率和科学决策 水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《青岛海 泰新光科技股份有限公司章程》（以下简称"《公司章程》"），结合公司的实 际情况制定本议事规则。 第二条 董事会是公司的常设机构，对股东会负责，执行股东会决议，维护 公司和全体股东的利益，负责公司发展目标和重大经营活动的决策。 第三条 董事会应当在《公司法》等相关法律、法规和规范性文件以及《公 司章程》规定的范围内依法行使职权，公平对待所有股东。董事会应当严格按照 股东会和《公司章程》的授权行事，不得越权形成决议。 第四条 董事会行使其职权，应当通过召开董事会会议审议，并形成董事会 决议后进行。 第二章 董 事 第五条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或破坏社会主义市场经济秩序， 被判处刑罚， ...

Company Overview - Qindao Haitai Newlight Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical endoscope instruments and optical products [1] - The main products include 4K fluorescence/white light laparoscopes, endoscope light source modules, camera adapters, and lenses [1] Financial Performance - For Q1 2025, the company reported a revenue of 147 million yuan, representing a year-on-year increase of 24.86% [1] - The net profit for the same period was 46.69 million yuan, showing a year-on-year growth of 21.45% [1] - The gross profit margin stood at 64.98% [1] Market Position - As of August 20, the closing price of the stock was 46.79 yuan, with a rise of 2.93% [1] - The rolling price-to-earnings (PE) ratio is 39.06, while the industry average PE is 59.32 [1][2] - The total market capitalization of the company is 5.609 billion yuan [1] Institutional Holdings - As of Q1 2025, there are 9 institutions holding shares in Haitai Newlight, all of which are funds, with a total holding of 10.4214 million shares valued at 407 million yuan [1]

Core Points - As of August 15, 2025, Haitai Xinguang (688677) closed at 45.51 yuan, with a slight increase of 0.46% and a turnover rate of 2.32% [1] - The company has been open to investor visits, providing its address and contact information for those interested in understanding its operations [2] - On August 15, the net outflow of main funds was 18.56 million yuan, accounting for 14.69% of the total transaction amount [3] Trading Information - On August 15, the fund flow for Haitai Xinguang showed a net outflow of 18.56 million yuan from main funds, while retail investors contributed a net inflow of 12.99 million yuan, representing 10.28% of the total transaction amount [3] - The total transaction amount on that day was 126 million yuan, with main funds making up a significant portion of the trading activity [3]

Core Viewpoint - Qingdao Haitai Newlight Technology Co., Ltd. has made significant advancements in the endoscope industry, particularly with its 4K fluorescence laparoscope, which features a unique fog removal technology that enhances surgical visibility and efficiency [1][3]. Group 1: Company Development and Technology - Haitai Newlight started with optical coating technology and successfully transitioned into the endoscope market by leveraging key technological opportunities, such as LED light sources and fluorescence laparoscopes [1][2]. - The company has achieved multiple critical technological breakthroughs, including a 4K fluorescence laparoscope that maintains distortion control below 10%, significantly better than the industry average [2][3]. - The self-developed laser coaxial coupling fog removal technology improves surgical visibility by 80% and is set to be mass-produced in 2024, enhancing market competitiveness [3]. Group 2: Innovation and Market Strategy - Haitai Newlight's multi-spectral lighting design has increased the light utilization rate in medical endoscopes from 60% to 85%, showcasing its commitment to innovation [4]. - The company is focusing on developing ultra-thin endoscopes, reducing the diameter from 10.5 mm to 2.7 mm, with ongoing efforts to achieve optical apertures smaller than 1 mm [5]. - Haitai Newlight has established a layered R&D system to ensure that its products meet the real needs of clinical applications, aiming to lead the high-end medical market [7]. Group 3: Market Position and Future Outlook - The domestic hard endoscope market is projected to reach 15.1 billion yuan by 2030, indicating rapid industry growth, yet most local manufacturers remain focused on low-end products [6]. - Haitai Newlight is adopting a dual-channel strategy, combining its own sales team with partnerships, such as the joint venture with China National Pharmaceutical Group, to enhance market reach [9]. - The company has achieved a stable overseas revenue share of 70%, balancing local R&D with overseas assembly to mitigate risks associated with international trade [10]. - Haitai Newlight emphasizes innovation over price competition, aiming to redefine industry standards through technological advancements and product upgrades [10].

证券日报网讯8月15日晚间，海泰新光发布公告称，公司计划于2025年8月25日(星期一)15：00-16：30举 行2025年半年度业绩说明会。 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-043 青岛海泰新光科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 08 月 25 日（星期一）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： （一）会议召开时间：2025 年 08 月 25 日（星期一）15:00-16:30 （二）会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心音频直播和网络互动 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播和网络互动 投资者可于 2025 年 08 月 18 日（星期一）至 08 月 22 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbeam.com 进行提问。公司将在说明会 ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

Group 1 - The core viewpoint of the article highlights the performance and valuation of Qindao Haitai Newlight Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1] - As of August 13, the company's stock closed at 49.2 yuan, down 1.15%, with a rolling price-to-earnings (PE) ratio of 41.07 times, and a total market value of 5.898 billion yuan [1] - The average PE ratio for the medical device industry is 57.48 times, with a median of 40.95 times, positioning Haitai Newlight at the 77th rank within the industry [1] Group 2 - As of the first quarter of 2025, nine institutions hold shares in Haitai Newlight, all of which are funds, with a total holding of 10.4214 million shares valued at 407 million yuan [1] - The company's main business includes the research, development, manufacturing, sales, and service of medical endoscope instruments and optical products, with key products being 4K fluorescence/white light laparoscopes, endoscope light source modules, and camera adapters/lenses [1] - The latest performance report for the first quarter of 2025 shows the company achieved an operating revenue of 147 million yuan, a year-on-year increase of 24.86%, and a net profit of 46.6887 million yuan, up 21.45%, with a gross profit margin of 64.98% [1]